Date published: 2025-10-25

1-800-457-3801

SCBT Portrait Logo
Seach Input

PRAMEF11 Inhibitors

PRAMEF11 inhibitors represent a specialized class of chemical compounds designed to modulate the activity of the PRAMEF11 protein, which is part of the PRAME family of proteins. PRAME proteins (Preferentially Expressed Antigen in Melanoma) belong to a larger group of leucine-rich repeat (LRR) proteins, characterized by their involvement in diverse cellular processes, including cell cycle regulation and protein-protein interactions. PRAMEF11, a specific member of this family, is thought to participate in molecular pathways linked to cell proliferation and differentiation, which are crucial for maintaining the balance between cell growth and apoptosis. Inhibitors targeting PRAMEF11 work by binding to specific regions of the protein, usually at the active or allosteric sites, leading to a reduction or alteration in its activity. These inhibitors can be categorized based on their structural motifs, which vary depending on the nature of the protein binding site, with some showing high specificity for PRAMEF11, while others may affect multiple PRAME family members.

The design of PRAMEF11 inhibitors often involves computational modeling to predict the most favorable interactions between the inhibitor and the protein. Structural features such as hydrogen bonding, hydrophobic interactions, and van der Waals forces play significant roles in the stability and affinity of these inhibitors. In terms of chemical composition, PRAMEF11 inhibitors can vary from small organic molecules to larger peptide-based inhibitors, each designed with the goal of maximizing specificity and minimizing off-target effects. Advanced screening techniques, such as high-throughput screening and molecular docking, are employed to identify potential PRAMEF11 inhibitors, followed by extensive biochemical characterization to determine their binding affinities, selectivity, and mechanism of action. The continuing refinement of PRAMEF11 inhibitors through structure-activity relationship (SAR) studies enhances our understanding of the protein's function at a molecular level and contributes to broader research on LRR-containing proteins.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

5-Azacytidine

320-67-2sc-221003
500 mg
$280.00
4
(1)

This compound could induce DNA demethylation specifically at the promoter region of the PRAMEF11 gene, leading to a decrease in gene expression by interfering with transcriptional activation.

Suberoylanilide Hydroxamic Acid

149647-78-9sc-220139
sc-220139A
100 mg
500 mg
$130.00
$270.00
37
(2)

Suberoylanilide Hydroxamic Acid may lead to hyperacetylation of histones associated with the PRAMEF11 gene, which could result in the downregulation of its transcription by altering chromatin accessibility.

5-Aza-2′-Deoxycytidine

2353-33-5sc-202424
sc-202424A
sc-202424B
25 mg
100 mg
250 mg
$214.00
$316.00
$418.00
7
(1)

As a cytosine analog, 5-Aza-2′-Deoxycytidine may incorporate into PRAMEF11's DNA during replication, inhibiting DNA methyltransferases and thereby reducing PRAMEF11 expression by promoter demethylation.

Triptolide

38748-32-2sc-200122
sc-200122A
1 mg
5 mg
$88.00
$200.00
13
(1)

This diterpene triepoxide could inhibit the expression of PRAMEF11 by obstructing the binding of essential transcription factors necessary for PRAMEF11 gene transcription.

Retinoic Acid, all trans

302-79-4sc-200898
sc-200898A
sc-200898B
sc-200898C
500 mg
5 g
10 g
100 g
$65.00
$319.00
$575.00
$998.00
28
(1)

By binding to retinoic acid receptors, Retinoic Acid could downregulate PRAMEF11 expression as part of a concerted change in gene expression that guides cellular differentiation.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Rapamycin could decrease PRAMEF11 expression by stalling the mTOR signaling pathway, which is crucial for protein synthesis and cell cycle progression, thereby reducing the protein synthesis machinery available for PRAMEF11.

Doxorubicin

23214-92-8sc-280681
sc-280681A
1 mg
5 mg
$173.00
$418.00
43
(3)

By intercalating into DNA, Doxorubicin could prevent the transcriptional machinery from accessing the PRAMEF11 gene, thereby decreasing its expression.

Curcumin

458-37-7sc-200509
sc-200509A
sc-200509B
sc-200509C
sc-200509D
sc-200509F
sc-200509E
1 g
5 g
25 g
100 g
250 g
1 kg
2.5 kg
$36.00
$68.00
$107.00
$214.00
$234.00
$862.00
$1968.00
47
(1)

Curcumin could downregulate PRAMEF11 by inhibiting the activity of NF-κB, a transcription factor known to be involved in the expression of various genes, potentially including PRAMEF11.

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$149.00
$470.00
$620.00
$1199.00
$2090.00
33
(3)

Trichostatin A may decrease PRAMEF11 expression by specifically inhibiting class I and II histone deacetylases, leading to an open chromatin structure that hinders the transcription of PRAMEF11.

D,L-Sulforaphane

4478-93-7sc-207495A
sc-207495B
sc-207495C
sc-207495
sc-207495E
sc-207495D
5 mg
10 mg
25 mg
1 g
10 g
250 mg
$150.00
$286.00
$479.00
$1299.00
$8299.00
$915.00
22
(1)

This isothiocyanate could decrease PRAMEF11 expression by selectively inhibiting histone deacetylases, which would result in chromatin remodeling and subsequent transcriptional repression of PRAMEF11.